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Graft-versus-Host Disease
Joanne Filicko-O’Hara, Dolores Grosso, Phyllis R. Flomenberg, Thea M. Friedman,
Janet Brunner, William Drobyski, Andres Ferber, Irina Kakhniashvili, Carolyn Keever-Taylor,
Bijoyesh Mookerjee, Julie-An Talano, John I. Wagner, Robert Korngold, Neal FlomenbergAlthough allogeneic hematopoietic progenitor cell transplant (HPCT) is curative therapy for many disor-
ders, it is associated with significant morbidity and mortality, which can be related to graft-versus-host dis-
ease (GVHD) and the immunosuppressive measures required for its prevention and/or treatment. Whether
the immunosuppression is pharmacologic or secondary to graft manipulation, the graft recipient is left at
increased risk of the threatening opportunistic infection. Refractory viral diseases in the immunocompro-
mised host have been treated by infusion of virus-specific lymphotyces and by unmanipulated donor lym-
phocyte infusion (DLI) therapy. L-leucyl-L-leucine methyl ester (LLME) is a compound that induces
programmed cell death of natural killer (NK) cells, monocytes, granulocytes, most CD81 T cells, and a small
fraction of CD41 T cells. We have undertaken a study of the use of LLME-treated DLI following T cell-
depleted allogeneic HPCT, specifically to aid with immune reconstitution. In this ongoing clinical trial, we
have demonstrated the rapid emergence of virus-specific responses following LLME DLI with minimal asso-
ciated GVHD. This paper examines the pace of immune recovery and the rapid development of antiviral
responses in 6 patients who developed viral infections during the time period immediately preceding or co-
incident with the administration of the LLME DLI.
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tion opportunistic infectionINTRODUCTION
Although allogeneic hematopoietic progenitor
cell transplant (HPCT) is curative therapy for many
disorders of lymphohematopoiesis, it is associated
with significant morbidity and mortality [1-5]. Much
of this risk can be traced to graft-versus-host di-
sease (GVHD) and the immunosuppressive measures
required for its prevention and/or treatment [6,7]. T
cell depletion (TCD) is an effective means of reducingDepartment of Medical Oncology, Kimmel Cancer Cen-
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result in delayed immune reconstitution. Whether
the immune suppression is pharmacologic or second-
ary to graft manipulation, the graft recipient is left
quantitatively or functionally lymphopenic, and at in-
creased risk of life-threatening/fatal opportunistic in-
fection. T lymphocytes, and in particular, CD41 T
lymphocytes are the most affected, and their absence
leaves the patient at particular risk for viral infection.
Refractory viral diseases in the immunocompro-
mised host have been treated by infusion of virus-
specific lymphocytes. Infusion of ex vivo activated
and/or expanded antivirus T cells has been used for
the treatment of cytomegalovirus (CMV) and Epstein-
Barr virus (EBV) [8,9]. Donor lymphocyte infusion
(DLI) therapy has been used after transplant for a vari-
ety of infections including persistent adenovirus [10],
CMV [11], EBV-lymphoproliferative disease (LPD)
[12,13], and hepatitis [14,15]. Both virus-specific and
unmanipulated donor lymphocytes have been docu-
mented to help restore T cell numbers [16,17], and1609
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been shown that recipients of allogeneic HPCT who
are deficient in CD81 cytotoxic T lymphocytes spe-
cific for CMV are specifically at risk for active
infection with CMV. In 1 study, patients who had re-
ceived CMV-specific clones of CD81 T cells derived
from donor bone marrow (BM) had improved recon-
stitution of their cellular immunity against CMV
[20]. Although the infusions of the donor-derived
CMV-specific clones were well tolerated and all pa-
tients had reconstituted CMV-specific cytotoxic T
lymphocytes by day 49 following HPCT, the virus-
specific CD81 CTL response persisted only in those
patients in whom CD41 helper responses recovered.
Virus-specific CTLs have been found to be effective
therapy for prevention of other posttransplant compli-
cations including EBV-LPD [21,22]. Unfortunately,
the infrastructure and resources required to make
this type of approach broadly applicable in the clinical
setting are not widely available, and the use of unma-
nipulated DLI therapy is often complicated by the de-
velopment of GVHD. Alternative approaches are
needed.
L-leucyl-L-leucine methyl ester (LLME) is a com-
pound taken up by cells through saturable facilitated
transport [23,24], and once intracellular, accumulates
in lysosomes and endosomes where dipeptidyl pepti-
dase I (DPPI) converts LLME to pro-apoptotic
metabolites. Because DPPI is expressed primarily by
cytotoxic granule-containing leukocytes, LLME
induces programmed cell death of natural killer (NK)
cells, monocytes, granulocytes, the majority of CD81
T cells, and a small fraction of CD41 T cells [24].
LLME has been effective in preventing GVHD in
mice and humans, but its human application had been
limited by toxicity to hematopoietic stem cells when
unseparated BM was treated prior to infusion [25-27].
In a phase I trial, HLA-matched or mismatched BM
grafts were incubated ex vivo with LLMEprior to infu-
sion [26]. Although LLME was effective in preventing
GVHD, toxicity to BM colony forming units (CFUs)
was noted, and 1 patient died from secondary graft fail-
ure. The study was therefore terminated. Aside from
the adverse effects of LLME on hematopoietic stem
cells (HSCs) directly exposed to the agent, other infu-
sional or delayed toxicities were not observed. Use of
DLI followingT cell-depleted transplantation circum-
vents the problem of HSC exposure to LLME. Addi-
tionally, this facilitates administration of precisely
defined doses of LLME-treated T cells, which may
allow for further reduction inGVHDrisk, as well as ac-
celerated CD41 T cell reconstitution.
We have undertaken a study of the use of LLME-
treated DLI following T cell-depleted allogeneic
HPCT specifically to aid with immune reconstitution.
In this clinical trial, we have demonstrated the rapid
emergence of virus-specific responses followingLLME DLI with minimal associated GVHD. This
paper presents data detailing the pace of immune
recovery and the rapid development of antiviral
responses in the 6 patients from the larger cohort
who developed viral infections during the time period
immediately preceding or coincident with the admin-
istration of the LLME DLI.MATERIALS AND METHODS
Eligibility
From February 2002 through July 2007, all
patients at Thomas Jefferson University Hospital
(TJUH) who had received a T cell-depleted (CD34-
enriched) HPCT were offered participation in a phase
I study of LLME-treated DLI to improve immune re-
constitution. The study was subsequently opened to
patients at the Medical College of Wisconsin. Patients
were eligible if they had an HLA-matched sibling
donor, HLA-matched unrelated donor, or an HLA
partially matched (single-antigen mismatch, 2-antigen
mismatch, or haplodisparate) related donor. Patients
were required to have undergone HPCT at least 28
days earlier and have a nondetectable antithymocyte
globulin (ATG) level (\2 mg/mL of serum for rabbit
ATG) within the prior 21 days. To be enrolled, pa-
tients must have demonstrated neutrophil engraftment
as defined by an absolute neutrophil count (ANC)
greater than 500 cells/mL for 3 consecutive days, but
have persistent CD4 lymphopenia (absolute CD41 T
cell count (ALC) \100 cells/mL). If a CD41 T cell
count was not obtainable, an absolute lymphocyte
count\100 cells/mL was considered prime facie evi-
dence of CD41 T cells\100 cells/mL. Patients were
excluded if there was evidence of overt relapse of the
underlying malignancy or persistent disease or active
GVHD. The presence of opportunistic infection was
not a contraindication to enrollment in this study.
The study was approved by the institutional review
boards at Thomas Jefferson University and the Medi-
cal College of Wisconsin and informed consent was
obtained for all participating patients.Conditioning Regimen and Supportive Care
All 6 patients reviewed in this paper received
a CD34-enriched HPCT following a preparative
regimen of fludarabine (Flu; 30 mg/m2, days 26
through 22), cytarabine (2 g/m2, days 26 though
22), andmelphalan (Mel; 200mg/m2, day21). All pa-
tients received rabbit ATG (Thymoglobulin, Sang-
Stat) during the peritransplant period. Prophylactic
antimicrobials consisted of an amphotericin product,
valacyclovir, and trimethoprim-sulfamethoxazole
(TMP-SMX). All patients received transfusion sup-
port with leukodepleted and irradiated cellular blood
Biol Blood Marrow Transplant 15:1609-1619, 2009 1611Antiviral Responses following LLME-Treated Lymphocyte Infusionsproducts. Patients who were CMV-seronegative re-
ceived CMV-seronegative blood products.
ATG Levels
Patients had blood drawn for ATG levels prior to
ATG administration, on the day of transplant, on
day 7 followingHPCT and generally weekly thereafter
as described previously [28]. At the beginning off this
trial, patients became eligible to receive LLME DLI
when the ATG level was\1.0 mg/mL. Subsequently,
based on further information about the pharmacoki-
netics and mechanisms of action of ATG, the protocol
was revised to allow for inclusion when the ATG level
became\2.0 mg/mL.
LLME Treatment
LLME was synthesized under GMP conditions by
Bachem (Switzerland). Immediately prior to use the
dry LLME powder was prepared in Normosol R at
a 500 mM concentration. Washed cells (blood or
apheresis product) were incubated with LLME at
a concentration of 10  106 cells/mL for 60 minutes.
Treated cells were washed once at 4C in Normosol,
and then twice at room temperature. Only products
with $80% depletion of NK cells (CD 16/561,
CD32) determined by flow cytometry were released
for infusion. The treatment dose was based on the
number of viable CD31 cells.
Immunophenotyping
Intracellular staining for perforin and surface
staining for lymphocyte subsets were performed, using
standard staining techniques as previously described
[29,30]. Flow cytometric analysis was performed using
the FACScan (Becton Dickinson, Fullerton, CA).
Antiviral Testing
Ex vivo ELISPOTassay
Peripheral blood monouclear cells (PBMC) were
separated from heparinized whole blood or buffy coats
using Ficoll-Hypaque density gradient centrifugation,
and cells were used either fresh or thawed from cryo-
preserved aliquots. The ex vivoELISPOTassay for de-
tection of interferon (IFN)-gwas based on the protocol
previously described [31]. Ninety-six-well polyvinyli-
dene difluoride backed plates (Millipore, Bedford,
MA) were coated overnight at 4C with 15 mg/mL of
anti-IFN-g monoclonal antibody (MAb) 1-D1 K
(Mabtech, Stockholm, Sweden). Wells were washed
and blocked with RPMI supplemented with 10% fetal
calf serum (FCS), penicillin, streptomycin, glutamine,
and 10 mM HEPES (R10) for 1 hour at 37C. Next,
each antigen was incubated with 250,000 PBMCs in
100 mL R10 in triplicate wells for 6 to 48 hours at
37C in 5% CO2. Wells were washed extensivelywith phosphate-buffered saline (PBS), 0.05% Tween
20, 1 mg/mL of biotinylated anti-IFN-g MAb 7-B6-1
(Mabtech) was added, and plates incubated at room
temperature for 3 hours. Next, wells were washed and
incubated with a 1:1000 dilution of alkaline phospha-
tase conjugate (Mabtech) for 2 hours. Wells were
washed again and incubated with alkaline phosphatase
substrate (Vector Labs, Burlingame, CA) for 30 min-
utes; the reaction was stopped with tap water. After
wells were air dried, large spots with fuzzy borders
were counted under a dissecting microscope. The
number of spot-forming cells (SFCs) per 106 PBMC
was calculated as themean number of SFCs in triplicate
microwells4. Antigen-specific precursor frequencies
were calculated as the mean number of SFCs in the an-
tigen-stimulated microwells minus the mean number
of SFCs in the control microwells.
Viral Titers
Whole blood samples were taken on all patients
weekly to screen for the reemergence of CMV using
quantitative real-time DNA PCR as previously
described [32-35]. Assays were performed by the clin-
ical laboratory at TJUH or at Viracor (Lee’s Summit,
MO). When clinically indicated, whole blood samples
were also analyzed for adenovirus, EBV, and BK virus
also using quantitative real-time DNA PCR [36-39].
In patients who developed reactivation of any virus as
demonstrated by a rising PCR titer, samples were fol-
lowed weekly until resolution, as evidenced by at least
2 consecutive undetectable titers.
CDR3-Size Spectratype Analysis/Spectratype
Complexity Index
As previously described [40], peripheral blood
lymphocytes (PBL) were enriched from donor and
patient PB samples by centrifugation over Ficoll-His-
topaque. CD41 and CD81 subsets were separated by
standard antibody-panning techniques and the en-
riched subset populations were solubilized in Ultra-
spec (Biotex Laboratories, Houston, TX). Vb
spectratype analysis of separated PBL from untreated
donor samples served as the reference point for full
repertoire complexity, and was used as the standard
of comparison for the LLME-treated, as well as post-
transplant samples. At the time of the posttransplant
analysis, all patients exhibited .90% donor chime-
rism, as determined by molecular analysis of short tan-
dem repeats [41].
Total RNA was isolated from Ultraspec samples
and cDNA was prepared, as previously described
[40]. Seminested polymerase chain reaction (PCR)
was performed using a panel of human Vb sense oligo-
primers and 2 Cb antisense oligoprimers, the second
Cb being fluorescently labeled. The PCR products
were run on a sequencing gel and analyzed by the
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systems, Foster City, CA). The complexity index
within a Vb family was determined as a percentage of
the number of peaks found in its spectratype histogram
in relation to the number of peaks in the corresponding
donorVb family histogram. AnyVb family with a com-
plexity index of$85% was considered to be fully com-
plex. Histogram peaks were identified by the
Genotyper Genescan program. Any donor or patient
sample exhibiting fewer than 12 evaluable Vb family
spectratypes was excluded.
Statistical Methods
Data from the ELISPOT assays were analyzed us-
ing a paired t-test to compare themean number of spots
in the quadruplicate control and experimental (anti-
gen-stimulated) microwells. The results were com-
pared between responders using the Mann-Whitney
U-test. Data comparisons for Vb repertoire analysis
were analyzed by the nonparametric Wilcoxon rank-
sum analysis. Value of P# .05 were considered statisti-
cally significant.T
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Patients
Twenty-three patients with hematologic malig-
nancies were enrolled in a study of LLME-treated
DLI to accelerate immune reconstitution after receiv-
ing CD34-enriched HPCT. Six of these 23 patients
represented a unique subset in that they each devel-
oped 1 or more viral infections during the time period
immediately before or concurrent with the administra-
tion of the LLME DLI. These patients demonstrated
a rapid and consistent pattern of response to their viral
infections, which is the subject of this report.
Five of these 6 patients received HPCT fromHLA
identical sibling donors, whereas 1 received HPCT
from an unrelated donor. One patient (patient #1)
was treated with steroids for adrenal insufficiency
and idiopathic pneumonia syndrome (IPS) and expired
35 days following LLMEDLI (134 days s/pHPCT). A
second patient (patient #3) also developed IPS and was
treated with steroids. This patient expired 100 days
following LLME DLI (148 days s/p HPCT).
Although both of these patients have been included
in this analysis of antiviral responses, neither is consid-
ered evaluable for immune reconstitution because of
the administration of corticosteroids for the treatment
of IPS.
LLME Treatment and Lymphocyte Subset
Depletion
Following LLME treatment of the DLI product as
described earlier, patients received a targeted number
Figure 1. LLME depletion. Flow cytometry of product prior to LLME treatment shows the presence of NK (CD56 or 161/CD32) cells, and CD31/
CD81 cells, and CD31/CD41 cells. However, following LLME treatment, cells that contain perforin, namely, the NK cells and a portion of CD81 cells,
are markedly depleted. The CD4 cell population is only minimally depleted in contrast (A). Following treatment with LLME, products showed adequate
depletions of NK and CD81 cells with a median 95.2% (range: 79.9-100) depletion of NK cells, 76.1% (range: 35.1-92.8) of CD31/CD81 cells, but only
31.0% (0-88.8) of CD31/CD41 cells (B).
Biol Blood Marrow Transplant 15:1609-1619, 2009 1613Antiviral Responses following LLME-Treated Lymphocyte InfusionsofCD31 cells/kg (Table 1). Initial cohorts of recipients
of unrelated donor grafts received a dose of 105 CD31
cells/ kg, whereas the first cohort of patients receiving
HLA identical sibling stem cell grafts received a dose
of 106 CD31 cells/ kg. Dose escalation was allowed
for each individual patient if that patient did not
develop GVHD and had also not recovered a CD41
T cell count of .200/mL. If at least 3 patients in 1
cohort received LLME-treated DLI at a dose withouttoxicity/GVHD, the next cohort received a dose 1 log
higher. The patients described here received either
106 CD31 cells/kg (HLA identical unrelated donor–
n 5 1; HLA identical sibling donors, n 5 2) or 107
CD31 cells/kg (HLA identical sibling donors, n 5 3).
Following treatment with LLME, flow cytometric
analysis showed as expected, a selective depletion of
cells containing perforin (Figure 1A). The products
showed adequate depletions of NK and CD81 cells
Figure 2. Reconstitution of perforin-positive cells. Following LLMEDLI, a product containing perforin-negative cells, patients were able to reconstitute
both perforin-negative and then perforin-positive cells. For the sample patient seen here, recovery of CD31/CD41 cells was apparent by day 37 after
LLME DLI (A). Earlier time points were measured (B) showing recovery of the same populations of cells but at lower numbers. The recovery of NK cells
heralded (third dot plot and third column) preceded the recovery of CD8 cells. Reconstitution of CD8 cells included both perforin-positive and
perforin-negative cells and preceded the recovery of CD4-positive cells.
1614 Biol Blood Marrow Transplant 15:1609-1619, 2009J. Filicko-O’Hara et al.with a median 95.2% (range: 79.9-100) depletion of
NK cells, 76.1% (range: 35.1-92.8) depletion of
CD31/CD81 cells, but only 31.0% (0-88.8) depletion
of CD31/CD41 cells (Figure 1B).
Immune Reconstitution
At the time of the first LLME-treated DLI treat-
ment, all patients demonstrated neutrophil engraft-
ment, but not lymphocyte engraftment. Two patients
(#1, #3) were not evaluable based on corticosteroid
use as described above. Posttreatment flow cytometric
analysis showed recovery of NK cells first, as would be
expected following T cell-depleted HPCT, including
both perforin positive and perforin negative cells,
followed by recovery of CD81 and then CD41 cells
(Figure 2). Following the first dose of LLME-treated
lymphocytes, 4 of 6 patients who were actively fighting
viral infections, achieved a CD31/CD41 count .100
cells/mL by 27.5 days postinfusion (range: 10-57
days) (Table 1). This recovery was not only rapid but
sustained. Data from a sample patient (#2) who devel-
oped adenovirus infection including hepatitis with
transaminases 5-10 times the upper limit of normal isshown (Figure 3A and B). Following LLME DLI,
reconstitution of lymphocyte subsets was prompt
and persistent. By 21 days after receiving DLI, he
had achieved a CD4 count of 333 cells/mL, and has
since maintained this count above 100 cells/mL
(Figure 3A). His recovery included reemergence of
both memory and naı¨ve T cells (Figure 3B), which
have also been sustained. In another patient (#5) who
had not achieved 100% donor chimerism at the time
he developed EBV-posttransplantation lymphoproli-
ferative disorders (PTLD), the pace of CD41 T cell
recovery was also rapid and sustained, but the CD4
response consisted primarily of memory T cells
(CD45 RO1/CD41). He subsequently converted to
100% donor cells, and maintained a stable number of
both memory and naı¨ve CD41 T cells (Figure 3C).
Antiviral Responses
We assayed for antiviral responses in the 6 patients
who developed infections following CD34-enriched
HPCT. These included reactivation of EBV (n 5 2),
CMV (n 5 4), and adenovirus (n 5 1). The infections
developed at a median of 51.5 days (range: 28-113
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Figure 3. Immune reconstitution following LLME DLI. Patients devel-
oped rapid and sustained reconstitution of lymphocyte subsets following
LLME DLI. As shown in this sample patient, this included CD31/CD41,
CD31/CD81, and CD32/CD56 or 161 cells (A) as well as both mem-
ory and naı¨ve CD4 cells (B). In 1 patient who had not converted to 100%
donor cells at the time he received LLME DLI, the recovery of memory
CD4 cells was more prominent (C).
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cally, 5 of 6 patients had a complete response as dem-
onstrated by resolution of the viral PCR titer. One
patient (#1) who developed idiopathic pneumonia syn-
drome and required high dose steroids, had a partial
resolution of his EBV titers, but had not completely re-
solved them prior to his death frommultisystem organ
failure, 35 days after receiving his first dose of LLME
DLI. Sample data are shown for 2 patients, 1 (#2) of
whom developed adenovirus hepatitis (Figure 4A and
B), and another (#4) who developed CMV infection
(Figure 4C andD). In both cases, one can see rapid res-olution of the viral PCR titers (Figure 4b and d). Sim-
ilar resolution of viral PCR titers were seen in 3 other
patients (#3, #5, and #6) at a range of 11-32 days (data
not shown). The final patient (patient #1) had partial
resolution of EBV pcr titer (94% reduction) prior to
his death from idiopathic pneumonia syndrome.
In addition, ELISPOT data demonstrated the
development of viral-specific response following
LLME DLI therapy. The patient with adenovirus
infection (patient #2) developed an adenovirus-specific
IFN-g response by his CD41 cells (Figure 4B). The
patient (patient #4) who developed the CMV infection
was found to have both a CMV-specific CD81 T cell
response (anti-A2 peptide) and a CD41 T cell re-
sponse (CMV ag) (Figure 4D), but no response to ad-
enovirus (not shown). Similarly, ELISPOT data from
patient #5 with EBV-PTLD showed an EBV specific
response following the LLME DLI (data not shown).
These responses were detected at a median of 11.5
days (range: 4-22) following LLME DLI therapy, and
were associated with regression of the viral infection
and resolution of circulating viral DNA by a median
of 20 days (range: 11-42) in the 5 patients who did
resolve their infections.
LLME DLI was given in conjunction with appro-
priate pharmacologic therapy in all cases. Patients with
EBV-PTLD (n 5 2) received rituximab, patients with
CMV (n5 4) or adenovirus (n5 1) received foscarnet,
ganciclovir, or valganciclovir, as clinically indicated
based on renal insufficiency and count recovery. Three
of 4 patients with CMV also received i.v. immuno
globulin as adjunctive therapy.Development of GVHD or Opportunistic
Infection
Severe GVHD (grade III) developed in only 1 of
these 6 patients (#3), a recipient of an HLA identical
sibling graft. This patient had received an initial dose
of 107 LLME DLI, but had not reached the target of
200 CD41 cells/mL, and thus received a second
LLME-treated DLI 43 days later. One week following
the second dose of LLME DLI, at 4.1  107 CD31
cells/kg (108) he developedGVHDof the skin and gas-
trointestinal (GI) tract.Spectratyping
CDR3-size spectratype analysis was used to
analyze PB samples to determine if there were any sig-
nificant differences in the complexity of the reconsti-
tuting CD41 and CD81 T cell subsets, between
donor and recipient (Figure 5). Reconstitution of
a complex repertoire was seen in all tested patients fol-
lowing LLME DLI. There were no significant differ-
ences in the level of VB family complexity between the
donor and ‘‘reconstituted’’ host.
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Figure 4. Antiviral responses. Sample data are shown for 2 patients. In panels A and B, one sees the data from a patient who developed adenovirus
hepatitis. Shortly after receiving the LLMEDLI, he began to clear the adenovirus with a 10-fold drop in PCR titers by 11 days s/p DLI (113 days s/p HPCT),
and complete resolution by 42 days s/p DLI (144 days s/p HPCT). This was associated with an adenovirus specific CD4 IFN-g response that was evident
at 147 and 175 days post-DLI. Sample from a second patient, who had developed CMV infection, is shown in panels C and D. Once again, the patient had
rapid resolution of CMV PCR titers with a significant drop within 6 days and complete resolution by 20 days s/p DLI (68 days s/p HPCT). He was also
found to have developed both a CMV-specific CD8 response (anti-A2 peptide) and CD4 response (CMV ag), but no response to adenovirus.
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Immune recovery following HPCT is slow, par-
ticularly following CD34-enriched or T cell-depleted
HPCT. Prior to immune recovery, patients are
susceptible to opportunistic infection including
CMV, adenovirus, EBV-PTLD, and BK virus. In
patients who receive unmanipulated grafts, GVHD
pharmacoprophylaxis and treatment may also lead
to profound immune suppression and similar types
of infections. These infections lead to significant
morbidity and mortality following HPCT. In a phase
I study using LLME DLI, 6 patients developed sig-
nificant viral infections during the immediate pre-
DLI time period. Following the LLME DLI, we
have seen rapid reconstitution of lymphocyte subsets
including CD31/CD81, CD31/CD41, and both
CD45RA1 and CD45RO1. This recovery, unlike
that seen with infusion of cultured virus- specific
CTLs, is sustained. It is associated with the emer-
gence of virus-specific clones, but also with the
development of a normal repertoire of T cells. Fur-
thermore, it is associated with an acceptable risk of
GVHD compared to unmanipulated DLI.LLME treatment is simple and not labor-inten-
sive.Within a few hours of phlebotomy or leukaphere-
sis, the product is ready for infusion. Thus, a patient in
need of DLI would have to wait only a few hours lon-
ger for this type of product than for an unmanipulated
product. This could be a significant advantage over the
use of virus-specific CTLs, which may take days or
weeks to prepare and require facilities not available
at many institutions. Infusions of virus-specific CTLs
can lead to rapid resolution of CMV disease. However,
the anti-CMV response is difficult to sustain in
patients who are otherwise still immune compromised
and lymphopenic. We have shown here that following
LLME DLI, the anti-CMV response is rapid and also
sustained.
In addition to the inability to maintain the antiviral
response, virus-specific CTLs do not provide immune
competence against other pathogens. In contrast,
LLME DLI, together with pharmacologic antiviral
therapy (foscarnet, cidofovir, ganciclovir), fosters
rapid virus-specific responses that are sustained. In
addition, these patients have quantitative evidence of
immune recovery across a panel of lymphocyte subsets
including cytotoxic cells, memory, and naı¨ve cells.
Figure 5. Vb spectratyping. Representative histograms of Vb spectra-
type analysis of the CD41T cells enriched from the peripheral blood of 1
of the patients/pairs. The repertoire complexity of the donor sample be-
fore LLME treatment (A), after LLME treatment (B), and reconstituting
in the patient post-LLME DLI (C) exhibit similar levels of complexity.
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of perforin containing cells capable of mediating cyto-
toxocity, providing a product that is enriched for
CD41 cells, but depleted of NK cells, and perforin
containing CD81 cells. Thus, the infused product is
relatively depleted of cytotoxic cells that might cause
GVHD or be targeted against specific pathogens while
it maintains T cells with helper activity. Although
CD81 T cells mediate direct cytotoxicity againstviral-infected targets, their generation in vivo is depen-
dent upon viral-specific CD41 helper T cells. Thus, in
the presence of replicating viral pathogens, our CD41
T cell-deficient patients receiving LLME DLI were
able to mount an appropriate immune response within
several days after the infusion.
In the setting of active viral infection, immune re-
covery following LLME DLI is relatively rapid. The
median time to recovery of a CD4 count .100/mL
was 27.5 days in these patients. This contrasts with
the slower recovery of patients treated with LLME
DLI who were not infected with viruses (data not
shown). The more rapid recovery kinetics of virally in-
fected patients likely reflects an initial reactive
lymphocytosis directed toward the specific viral path-
ogen, while these patients as well as the uninfected
patients subsequently undergo a broader, infection-
independent expansion of the infused T lymphocytes.
In addition, the response was durable. Patients did not
relapse in terms dropping lymphocyte counts. More
importantly, no patient had relapse of viral disease at
any time following LLME DLI. This contrasts with
patients who have received only pharmacologic ther-
apy or virus-specific CTLs who unfortunately often
suffer relapse of the viral disease [9].
Although GVHD has long been associated with
DLI, in this small group of patients this has not been
an issue, except for 1 patient who did receive a higher
dose of cells and likely was developing GVHD from
the initial DLI just as a second larger DLI was admin-
istered. These patients were treated as part of a study
that had as its primary endpoint the development of
a CD4 count .100 and as a secondary endpoint the
development of GVHD. It would be premature to
comment on the risk of GVHDwith LLMEDLI until
a larger cohort of patients have received this therapy.
However, in the small number of patients described
here, we have seen encouraging results with very little
GVHD.
In the absence of severe GVHD, LLME-treated
DLI appears to be a viable treatment option that has
simplicity along with a rapid and durable immune
recovery as major advantages. In addition, the rapid
reconstitution of more broad-based T cell immunity
including a complex T cell repertoire is also an advan-
tage. Further trials are required to assess the utility
of this therapy in the treatment of established viral
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